Language

CAS No. 287714-41-4 | Rosuvastatin

Name:Rosuvastatin CAS No.287714-41-4 MF:C22H28FN3O6S MW:481.54 Purity:97% Package: 10g,25g,50g,100g,250g Worldwide Delivery

Categories：

Pharmaceutical Intermediates

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 287714-41-4 | Rosuvastatin

Synonyms:7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoicacid;

ROSUVASTATIN-D3SODIUMSALT;

(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-MethylMethanesulfonaMido)-6-(propan-2-yl)pyriMidin-5-yl]-3,5-dihydroxyhept-6-enoicacid;

(3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoicacid;

R-2:TERT-BUTYL-(+)7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-METHYLSULFONYLAMINO)PYRIMIDINE-5-YL]-(3R,5S)-DIOXANE-(E)-6-HEPTENATE;Rosuvastatin;RosuvastatinImpurity21;

Specification:

ITEMS	SPECIFICATION
CAS	287714-41-4
MF	C22H28FN3O6S
MW	481.54
Melting point	161.9 °C
Boiling point	745.6±70.0 °C
Density	1.368±0.06 g/cm3
Acidity coefficient	4.25±0.10
Color	white to light brown
Solubility	DMSO (a little), methanol (a little), water (a little)
Form	Solid
Storage condition	Sealed in dry,Store in freezer, under -20°C

Overview:

Rovastatin, also known as rosuvastatin and Crestor, is a fully synthetic β-hydroxy-β-methylvaleryl coenzyme A (HMG-CoA) reductase inhibitor with high liver selectivity. The synthesis of source cholesterol can significantly reduce serum cholesterol levels, while also reducing the levels of low-density lipoprotein-cholesterol (LDL-C), total cholesterol and apolipoprotein (apo) B, and increasing high-density lipoprotein-cholesterol (LDL-C). Cholesterol (HDL-C) level has anti-atherosclerotic effects and is effective in various types of dyslipidemia such as primary hypercholesterolemia and mixed hypercholesterolemia. It is well tolerated and adversely affected. Mild reaction.

Pharmacological effects: Rovastatin has an obvious blood-lipid-lowering effect. Generally, statins can reduce low-density lipoprotein cholesterol (LDL-C) levels by 17% to 54%. The phase II clinical trial results of rovastatin show that when the dose is 80 mg, it can reduce LDL-C by 65%, which is the best efficacy among statins at present. Rovastatin increases the number of LDL receptors. In human hepatoma, rovastatin increases the amount of LDL receptor mRNA approximately 10 times more than pravastatin

Structure:

Although rovastatin has the common pharmacodynamic group dihydroxyheptanoic acid part of statins, the rest of its molecular structure is very different from other similar drugs. The presence of the polar methanesulfonamide group makes it less lipophilic. . This means that its passive diffusion capacity is low and it is difficult to enter non-hepatocytes. However, it can be taken up in large amounts by liver cells through the selective organic anion transport process, and has the characteristics of selective distribution and acting on HMG-CoA reductase in the liver. At the same time, the relatively water-soluble nature of its structure also enables it to avoid the defect of extensive metabolism of cytochrome P450 before elimination, and greatly reduces the probability of interaction with other drugs.

Package and transportation :

Package: 10g,25g,50g,100g,250g